key: cord-1002433-9wqu8ezq
authors: Bašić‐Jukić, Nikolina; Atić, Armin
title: Additional eculizumab dose and tacrolimus discontinuation for treatment of COVID‐19 in a kidney transplant recipient with aHUS
date: 2021-07-24
journal: Ther Apher Dial
DOI: 10.1111/1744-9987.13710
sha: 2cdabca69740d684a427d62f23d44d2492e2bce7
doc_id: 1002433
cord_uid: 9wqu8ezq

nan

given on the second day, and her scheduled dose was administered on the 18th day of the disease. On the 21st day, a control chest CT scan showed regression of lung infiltration, which enabled reinstitution of tacrolimus at reduced doses. The patient remained afebrile throughout the hospital stay, exhibited no signs of hemorrhage or respiratory distress, and the kidney function remained stable. Two consecutive negative PCR tests were obtained on hospital days 21 and 22, and she was discharged. On follow-up, 4 days later, she was asymptomatic. Laboratory tests were within reference ranges (hemoglobin 132 g/L, WBC 4.8 Â 10 9 /L, platelets 296 Â 10 12 /L, C-reactive protein 1.6 mg/L, D-dimers 0.56 mg/L, creatinine 84 μmol/L, creatinine clearance 102 mL/min). Serum protein electrophoresis showed no abnormalities, complement levels, free hemoglobin, and LDH were normal. Blood PCR for BK, JC, EBV, and CMV were negative, and urine PCR was positive for JC polyomavirus.

Trimarchi et al described a case of COVID-19 in a KTR with aHUS. 8 They opted for continuing tacrolimus and withholding MMF, together with eculizumab administration. This strategy failed to prevent respiratory failure and endothelial cell injury. However, the patient improved and was discharged home. We considered the potential risk of tacrolimus-associated thrombotic microangiopathy warranted a different approach to immunosuppression than reported in most KTRs with COVID-19. 9, 10 Cognard et al opted for almost the same strategy as was used in our case. However, they postponed the initially scheduled injection of eculizumab, and later administer eculizumab at a higher dose (1200 mg). They also ceased tacrolimus with a favorable outcome. 11 It is important to note that no evidence-based recommendations for immunosuppression management in COVID-19 exist. Eculizumab is currently under evaluation, and its role in COVID-19 will be further elucidated (National Library of Medicine [NLM], NCT04288713). The complex interplay of the prothrombotic state caused by COVID-19, potential alternative pathway activation in aHUS, and the need to preserve graft function required

COVID-19, microangiopathy, hemostatic activation, and complement

COVID-19: complement, coagulation, and collateral damage

Complement as a target in COVID-19?

Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment

Atypical hemolytic uremic syndrome

Atypical HUS relapse triggered by COVID-19

Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with Eculizumab: a systematic review and meta-analysis

SARS-CoV-2 and atypical hemolytic uremic syndrome

Thrombotic microangiopathy in a renal allograft: single-center five-year experience

COVID-19 and kidney transplantation: results from the TANGO international transplant consortium

COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report